The Science & History of Psilocybin

Psilocybin mushrooms have been used by indigenous cultures for thousands of years — for healing, for ceremony, for communion with the unseen. Long before Western science turned its attention to these fungi, communities across Mesoamerica, North America, and beyond understood them as medicine. That knowledge was suppressed for decades. It is returning now.

What Psilocybin Is

Psilocybin is a naturally occurring compound found in certain species of fungi, including Psilocybe cubensis. When consumed, the body converts it to psilocin, which interacts with serotonin receptors — particularly 5-HT2A — producing changes in perception, cognition, and emotional processing. The experience typically lasts four to six hours, though its effects on how a person understands themselves can last considerably longer.

Physiologically, psilocybin is non-addictive and has extremely low toxicity. You cannot become physically dependent on it. The risks that exist are primarily psychological — which is why set, setting, preparation, and integration are not optional considerations. They are the practice.

What the Research Shows

Modern clinical research — led by institutions including Johns Hopkins, NYU, and Imperial College London — has produced striking results across a range of conditions.

Depression. Multiple trials have shown significant reductions in treatment-resistant depression following one to two guided psilocybin sessions. In some studies, the effect size exceeded that of leading antidepressants.

Anxiety. Studies with end-of-life patients showed dramatic reductions in death anxiety and existential distress — effects that persisted at six-month follow-up.

Addiction. Early trials on tobacco and alcohol addiction have shown promise beyond what existing treatments achieve, with some participants maintaining abstinence years later.

The default mode network. Neuroimaging research suggests psilocybin temporarily quiets the default mode network — the brain's self-referential storytelling system — allowing new patterns of connection to form. Many people describe this as the feeling of stepping outside a story they didn't know they were living inside.

This research is young. The mechanisms are not fully understood. We share it not as proof of outcome but as honest accounting of where the science stands.

A Note on Microdosing

Microdosing — taking sub-perceptual doses on a structured schedule — has attracted significant popular interest. The clinical evidence base is still developing, and reported benefits (improved focus, emotional resilience, creativity, reduced anxiety) are largely self-reported at this stage. Controlled trials are underway. We think it is worth being honest about that gap between what people experience and what has been formally established.

What we do know: at sub-perceptual doses, the risk profile is low, and for many people the practice has meaningfully improved their daily experience. We offer guidance on how to approach it responsibly.

A Note on Legal Status

Psilocybin's legal status is changing, unevenly and quickly. Oregon and Colorado have established regulated frameworks. Several cities have decriminalized possession. Federally in the United States, psilocybin remains a Schedule I substance. Internationally, the picture varies widely.